Lisa A. Jackson, MD, MPH

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Lisa.A.Jackson@kp.org

Curriculum vitae (CV)

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia

Recent publications

Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Wolff MC. Immunogenicity and safety of varying dosages of a monovalent 2009 h1n1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and seniors. J Infect Dis. 2012 Sep;206(6):811-20. Epub 2012 Jul 10. PubMed

Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged =50 years. Vaccine. 2012 Aug 3;30(36):5437-44. doi: 10.1016/j.vaccine.2012.05.076. Epub 2012 Jun 20. PubMed

Jackson LA. Association between statins and mortality. J Infect Dis. 2012 Jul 15;206(2):303-4; author reply 304-5. Epub 2012 May 8. PubMed

Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, Daley MF, Jackson L, Jacobsen SJ. Safety of zoster vaccine in adults from a large managed care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012 May;271(5):510-20. doi: 10.1111/j.1365-2796.2011.02474.x. Epub 2011 Nov 22. PubMed

Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, Jackson LA, Nordin J, Lieu T, Belongia EA, Fireman B. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012 May;129(5):809-14. Epub 2012 Apr 2. PubMed

Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012 Jun 13;30(28):4240-8. Epub 2012 Apr 23. PubMed

Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM, VSD Rapid Cycle Analysis Influenza Working Group, Jackson LA. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012 Mar 2;30(11):2024-31. doi: 10.1016/j.vaccine.2012.01.027. PubMed

Nelson JC, Cook AJ, Yu O, Dominguez C, Zhao S, Greene SK, Fireman BH, Jacobsen SJ, Weintraub ES, Jackson LA. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:62-71. doi: 10.1002/pds.2324. PubMed

Hambidge SJ, Ross C, Glanz J, McClure D, Daley MF, Xu S, Shoup JA, Narwaney K, Baggs J, Weintraub E and the Vaccine Safety Datalink Team. Trivalent inactivated influenza vaccine is not associated with sickle cell crises in children. Pediatrics. 2012 Jan;129(1):e54-9. doi: 10.1542/peds.2011-1294. Epub 2011 Dec 12. PubMed

Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc. 2011 Oct;59(10):1899-907. doi: 10.1111/j.1532-5415.2011.03586.x. Epub 2011 Sep 13. PubMed